On 29th, AIBIT announced that Mecox Curemed, a company specializing in the development of new drugs, has succeeded in securing additional strains for producing the anticancer substance, Tubulysin.

AIBIT has accelerated new drug development business since January 13th through investment in Mecox Curemed. The acquisition of additional strains is expected to speed up the development of anticancer drugs.


In order to speed up the development of anticancer drug M001 using Tubulysin, which is being developed by Mecox Curemed, there is a need for a mass production system of Tubulysin. Last year, Mecox Curemed succeeded in separating MEHO 001 (Archangium gephyra MEHO 001), a strain that produces Tubulysin from domestic soil. This time, MEHO 002, a series of MEHO 001 strains, was obtained.

Mecox Curemed said that MEHO 002 will be a significant turning point in the development of mass production process, because the production efficiency of Tubulysin is much higher than the existing MEHO 001. The firm already completed the registration process for the domestic and international organizations of MEHO 002, and the process for registering a patent is ongoing.

Tubulysin, the main ingredient of M001, which is being developed by Mecox Curemed, is known to have up to 100 times stronger anticancer effects than existing anticancer substances. However, due to its complex chemical structure, difficulties in chemical synthesis and cultivation have made it hard to secure substances.

Now, Mecox Curemed’s team is speeding up the development of mass production process for Tubulysin through ongoing collaborative research with Hoseo University's Myxobacteria research team, which has Korea Myxobacteria bank.

Established in 2006, Mecox Curemed’s most popular pipeline is the development of a mass extract and nano-drug delivery system for Tubulysin, a powerful anticancer substance. Once the development of the mass production process for Tubulysin is completed, it is expected that the addition of pipelines for the solid cancer drugs, M004 and M005, will also be easy. In addition, the sale of Tubulysin itself will mean a lot.





Copyright © acrofan All Right Reserved